Biomea Fusion (NASDAQ:BMEA) Price Target Raised to $7.00

Biomea Fusion (NASDAQ:BMEA) had its price objective lifted by Citigroup from $6.00 to $7.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

BMEA has been the topic of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. Rodman & Renshaw started coverage on Biomea Fusion in a research note on Tuesday, January 13th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Biomea Fusion in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.75.

Biomea Fusion Price Performance

NASDAQ BMEA opened at $1.32 on Friday. Biomea Fusion has a twelve month low of $0.87 and a twelve month high of $3.08. The stock has a market cap of $95.44 million, a P/E ratio of -1.01 and a beta of -0.20. The company’s 50-day simple moving average is $1.29 and its 200 day simple moving average is $1.42.

Institutional Investors Weigh In On Biomea Fusion

A number of large investors have recently bought and sold shares of BMEA. Vanguard Group Inc. increased its holdings in Biomea Fusion by 15.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,170,066 shares of the company’s stock valued at $4,384,000 after purchasing an additional 290,376 shares in the last quarter. Aisling Capital Management LP raised its holdings in shares of Biomea Fusion by 156.5% in the second quarter. Aisling Capital Management LP now owns 2,048,757 shares of the company’s stock valued at $3,688,000 after buying an additional 1,250,000 shares during the last quarter. Marshall Wace LLP lifted its position in Biomea Fusion by 293.7% during the 4th quarter. Marshall Wace LLP now owns 1,160,351 shares of the company’s stock worth $1,439,000 after buying an additional 865,618 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Biomea Fusion during the 4th quarter worth about $783,000. Finally, Mariner LLC grew its holdings in Biomea Fusion by 145.1% during the 4th quarter. Mariner LLC now owns 585,632 shares of the company’s stock worth $726,000 after acquiring an additional 346,702 shares during the last quarter. 96.72% of the stock is currently owned by institutional investors.

Biomea Fusion News Summary

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.